Preventive Cancer Vaccine

Despite recent advances in diagnosis, prevention, and treatment, cancer continues to be the world’s most common cause of death and affects millions of people globally. The development of cancer vaccines (CVs) is advancing significantly as a result of the US FDA’s clearance of several preventative CVs, including Gardasil (Merck), Cervarix (Glaxosmithkline), and the therapeutic vaccine Sipulencel-T (Provenge). The idea of treating cancer via cellular immunotherapy has gained support thanks to the approval of these vaccinations. Recent results indicate that immunotherapy may be an effective tool in the fight against cancer. Immunotherapy more precisely targets cancer cells than conventional surgery, chemotherapy, or radiotherapy, providing patients the chance to have higher response rates, a better quality of life, or possibly a cure for their condition. CVs may be created to target tumor-specific antigens (TSAs), also known as neoantigens, tumor-associated antigens (TAAs), cancer germline antigens, virus-associated antigens, or TAAs. With various types of adjuvants, the CVs could be cell-based (such as the dendritic cell (DC) vaccine provenge (sipuleucel-T) targeting prostatic acid phosphatase for metastatic prostate cancer (PC)), peptide/protein-based, or gene (DNA/RNA)-based. Neoantigens are tumor-specific compounds that can be presented by MHC molecules and recognized by T cells, making them ideal immunological targets for enhancing treatment specificity and reducing the risk of nonspecific autoimmunity. The CV has the potential to 266 treat the condition by targeting specific private epitopes and shared antigens. By reducing the frequency and duration of vaccinations, the feasibility of CVs can be improved without compromising effectiveness. However, the extensive length of in vivo research and the multitude of potential variations in vaccination procedures have hindered their optimization. Current CV trials are limited by the failure of immunologic assays to track clinically significant indicators of response. Recent advancements in the measurement and phenotyping of circulating tumor cells (CTCs) in breast cancer patients suggest that CTCs may play a role in assessing the efficacy of vaccine-based immunotherapy. Certain types of head and neck cancers, as well as cervical, vulvar, vaginal, and anal cancers, have all been associated with the human papillomavirus (HPV). Therefore, effective HPV vaccination offers an opportunity to reduce the morbidity and mortality associated with HPV.